Azenta, Inc. (AZTA)
| Market Cap | 827.34M -33.3% |
| Revenue (ttm) | 596.48M +1.8% |
| Net Income | -173.34M |
| EPS | -3.78 |
| Shares Out | 46.09M |
| PE Ratio | n/a |
| Forward PE | 30.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,044,447 |
| Open | 19.03 |
| Previous Close | 19.22 |
| Day's Range | 17.88 - 19.17 |
| 52-Week Range | 17.11 - 41.73 |
| Beta | 1.43 |
| Analysts | Strong Buy |
| Price Target | 38.40 (+113.93%) |
| Earnings Date | May 5, 2026 |
About AZTA
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sampl... [Read more]
Financial Performance
In fiscal year 2025, Azenta's revenue was $593.82 million, an increase of 3.55% compared to the previous year's $573.45 million. Losses were -$55.76 million, -66.18% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for AZTA stock is "Strong Buy." The 12-month stock price target is $38.4, which is an increase of 113.93% from the latest price.
News
Azenta, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Azenta, Inc. (NASDAQ: AZTA). The investigation focuses on Azenta's executiv...
Azenta Earnings Call Transcript: Q2 2026
Q2 saw a 3% organic revenue decline and margin compression due to execution gaps and soft North America demand, offset by growth in Europe, Asia, and recurring revenue streams. Guidance for 2026 was revised downward, with long-range targets pushed out a year, but leadership changes and operational improvements are underway.
Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029
FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 million FY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared...
Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast
BURLINGTON, Mass., April 29, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2026 earnings which ended on March 31, 2026, on Wednesday, May 6, 2026, before the mar...
Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
BURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026.
Azenta price target lowered to $35 from $45 at Evercore ISI
Evercore ISI lowered the firm’s price target on Azenta (AZTA) to $35 from $45 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…
Azenta price target lowered to $35 from $40 at Jefferies
Jefferies analyst Matthew Stanton lowered the firm’s price target on Azenta (AZTA) to $35 from $40 and keeps a Buy rating on the shares. The firm is updating its model…
Azenta Transcript: M&A announcement
The acquisition expands European presence, leverages automation synergies, and positions for scalable growth in life sciences. Minimal CapEx is required, with commercial investments driving future revenue and margin expansion. 2026 will be dilutive, but accretive from 2027.
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities
BURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquire...
Azenta Transcript: 47th Annual Raymond James Institutional Investor Conference
The company is executing a turnaround with a focus on operational excellence, margin expansion, and commercial effectiveness. Key initiatives include decentralization, sales force transformation, and ABS-driven process improvements, with strong free cash flow and EBITDA growth targeted over the next three years.
Azenta to Participate in Raymond James 47th Annual Institutional Investor Conference
BURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on...
Azenta, Frontier Space announce strategic partnership
Azenta (AZTA) announced a strategic partnership with Frontier Space, a company in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration a...
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
BURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduc...
Azenta price target lowered to $45 from $50 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Azenta (AZTA) to $45 from $50 and keeps an Outperform rating on the shares, calling shares “interesting” after the…
Azenta price target lowered to $30 from $39 at TD Cowen
TD Cowen lowered the firm’s price target on Azenta (AZTA) to $30 from $39 and keeps a Hold rating on the shares. The stock is down over 20% post earnings…
Azenta Earnings Call Transcript: Q1 2026
Q1 revenue was $149M, up 1% reported but down 1% organically, with margin pressures from quality issues and regional mix. FY2026 guidance for 3%-5% organic growth and 300 bps EBITDA margin expansion reaffirmed, with acceleration expected in the second half as investments and market conditions improve.
Azenta reports Q1 EPS 9c, consensus 13c
Reports Q1 revenue $148.64M, consensus $147.1M. “We delivered revenue performance consistent with our expectations. We also generated strong free cash flow in the quarter, reflecting our continued foc...
Azenta backs FY26 organic revenue view 3%-5%
Backs FY26 adjusted EBITDA margin expansion 300 basis points.
Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025
BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2025.
Azenta Transcript: AGM 2026
A transformative year featured strong cash reserves, margin expansion, and a $250M share repurchase. Four shareholder proposals, including board elections and an equity plan amendment, were all approved. Strategic plans include divesting B Medical by March 2026.
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before t...
Azenta price target raised to $39 from $35 at TD Cowen
TD Cowen analyst Brendan Smith raised the firm’s price target on Azenta (AZTA) to $39 from $35 and keeps a Hold rating on the shares. The firm adjusted price targets…
Azenta price target raised to $39 from $35 at TD Cowen
TD Cowen raised the firm’s price target on Azenta (AZTA) to $39 from $35 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic…
Evercore ISI upgrades four, downgrades six in MedTech and Tools
As previously reported, Evercore ISI upgraded Agilent (A) to Outperform from In Line with a price target of $160, up from $155, upgraded Azenta (AZTA) to Outperform from In Line…
Azenta upgraded to Outperform from In Line at Evercore ISI
Evercore ISI upgraded Azenta (AZTA) to Outperform from In Line with a price target of $50, up from $34.